Outcomes-based, risk-sharing agreements are an option for manufacturers seeking to mitigate additional price regulation and access restrictions proposed by payers, politicians, and other stakeholders. When it comes to implementation, nearly all stakeholders continue to be somewhat skeptical of outcomes-based contracts (OBCs).
Consultants with Charles River Associates solicited ideas and opinions of payers and drug manufacturers through separate live discussions to gain a deeper understanding of how to overcome roadblocks to OBCs. In this article, we share the ideas we heard, examine the obstacles, and provide examples of how payers and manufacturers can collaborate to share risk and improve patient outcomes.
To read the article, click the link below.
Policy solutions to improve access to fertility treatment and optimise patient care: consensus from an expert forum
Infertility affects more than 17% of people of reproductive age globally, yet access to ART remains uneven and often out of reach.